Protocols

Clozel’s Actelion R&D spinout gets a name; GSK’s new CEO won’t make as much as her predecessor

Jean-Paul Clozel

→ Jean-Paul Clozel has a name for his biotech spinout. Once J&J’s $30 billion deal to acquire Actelion goes through, the R&D side of the business will launch under the name Idorsia. When the deal was originally announced, Clozel had pencilled in NewCo for his next venture.

→ Aurinia $AUPH took advantage of a rising share price to round up $150 million in a new offering. But the stock took a beating Tuesday after the biotech decided to offer the shares at a deep discount.

→ New GSK CEO Emma Walmsley won’t be paid as well as her predecessor, Andrew Witty. The pharma giant overall is cutting the pay packet by 25% for Walmsley, who is stepping up to her first job as CEO. The company performed a review of its pay practices, aware of some criticism it’s been getting as generic Advair makes its way to the market.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BioNJ CEO Summit 2017